European CDMO Selected as Manufacturing Partner for Cell Therapies

Contract development and manufacturing organisation MaSTherCell (Belgium) has been chosen by Kangstem Biotech as manufacturing partner for its European clinical trial of FURESTEM-AD(R).

Kangstem, a developer of cell therapies using mesenchymal stem cells derived from human umbilical cord blood, is moving into late phase clinical trials in Korea and strengthened by this expertise, has now taken the opportunity to enter into Europe with its innovative cell therapy products. “The European clinical trial of Furestem-AD will be a milestone for our company. We believe that MaSTherCell's expertise and experience will be the key to enable it,” said Mr. Tae Wha Lee, CEO of Kangstem.

“Kangstem’s allogeneic human umbilical cord blood-derived stem cell based project fits perfectly in MaSTherCell’s long term strategy to provide services across all segments of the cell therapy field,” said Romain de Rauville, Business Development Manager and Head of Europe at MaSTherCell. “Being selected by a Korean cell therapy company really portrays MaSTherCell’s expertise and agility in assisting our partners with their globalisation. Kangstem’s efficient manufacturing process will further increase MaSTherCell’s expertise and skills to broaden the impact of both companies on the cell therapy field.”

The partnership provides Kangstem access to MaSTherCell’s cell therapy manufacturing expertise, capabilities and new facility offering efficient clean room set-up for its large-scale manufacturing process. If desired, MaSTherCell’s global facilities further allow Kangstem to easily expand to other continents. This puts Kangstem in a fast-track position to provide its innovative cell therapy products to more patients.

MaSTherCell is a subsidiary of Orgenesis Inc. through Masthercell Global Inc.